OptiNose (NASDAQ:OPTN) Announces Earnings Results, Beats Estimates By $0.67 EPS

OptiNose (NASDAQ:OPTN) released its earnings results on Wednesday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.67, Zacks reports. The company had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.02 million.

OptiNose Trading Down 0.4 %

OPTN stock traded down $0.04 on Thursday, hitting $9.13. 55,370 shares of the company’s stock traded hands, compared to its average volume of 61,720. The stock has a market cap of $91.85 million, a price-to-earnings ratio of -2.17 and a beta of -0.30. OptiNose has a 1-year low of $4.82 and a 1-year high of $22.50. The stock has a fifty day moving average of $6.19 and a 200-day moving average of $8.01.

Analyst Ratings Changes

A number of research firms recently commented on OPTN. Lake Street Capital lowered shares of OptiNose from a “buy” rating to a “hold” rating and lowered their price objective for the company from $17.00 to $9.00 in a research note on Thursday, March 20th. HC Wainwright reissued a “neutral” rating and issued a $9.00 price objective (down previously from $18.00) on shares of OptiNose in a research note on Friday, March 21st. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $9.00 target price (down previously from $15.00) on shares of OptiNose in a research note on Friday, March 21st.

Insider Activity

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total transaction of $33,729.04. Following the sale, the chief executive officer now owns 126,931 shares in the company, valued at approximately $671,464.99. The trade was a 4.78 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders sold 8,213 shares of company stock worth $43,643. Insiders own 2.30% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.